Status:
COMPLETED
Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prevention in Children With Sickle Cell Anemia
Lead Sponsor:
Makerere University
Conditions:
Sickle Cell Anemia
Malaria
Eligibility:
All Genders
6-12 years
Phase:
PHASE3
Brief Summary
Malaria is fatal and increases the risk of death among children with sickle cell anemia. Chemoprophylaxis significantly improves quality of life in these children. In Uganda Chloroquine is the drug of...
Detailed Description
Malaria is fatal and increases the risk of death among children with sickle cell anemia. Chemoprophylaxis significantly improves quality of life in these children. In Uganda Chloroquine is the drug of...
Eligibility Criteria
Inclusion
- Children aged 6 months to 12 years attending sickle cell clinic in Mulago Hospital during the study period with a negative peripheral smear for parasites, adherence to appointment visits, consent by care takers to participate in the study.
Exclusion
- Patients with known allergy to sulfonamides, Patients with severe illnesses requiring urgent admission, Patients with documented treatment for malaria in the past one month with Sulfadoxine- Pyrimethamine. Patients on cotrimoxazole prophylaxis
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2007
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT00399074
Start Date
October 1 2006
End Date
February 1 2007
Last Update
July 2 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mulago Hospital
Kampala, Central Region, Uganda, 256